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Abstract
Purpose This study aimed to explore peoples needs and expecta-
tions of written medicines information (WMI), and to determine the
barriers and facilitators experienced or perceived in the context of
WMI provision and use.
Methods We conducted eight focus groups with 62 participants
over 6 weeks in late 2008 in New South Wales, Australia. Using a
semi-structured topic schedule and examples of WMI from Australia
and other English-speaking countries as a guide, we explored themes
relevant to WMI, including participant experiences, attitudes, beliefs
and expectations.
Findings Our ﬁndings suggest less than half had previously received
WMI, with many unaware of its availability. Many, but not all,
wanted WMI to supplement the spoken information they received
but not to replace it, and it was predominantly used to facilitate
informed choice, ascertain medicine suitability and review instruc-
tions. The current leaﬂets were considered technical and long, and a
summary leaﬂet in addition to comprehensive information was
favoured. Accurate side-eﬀect information was the most important
element that participants desired. The most common barriers to
eﬀective WMI use were time constraints and patient conﬁdence,
with participants citing empowerment, time and health-care profes-
sional (HCP)–patient relationships as important facilitators.
Conclusion The ﬁndings provide insight and understanding of
peoples needs and expectations, and clarify issues associated with
use and non-use of WMI. Challenges include addressing the
barriers, especially of time and HCP attitudes to drive changes to
workplace practices, and learning from the facilitating factors to
encourage awareness and accessibility to WMI as a tool to empower
patients.
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Introduction
Increasingly priority is being given to patient-
centred care, underpinned by a model of shared
decision making about treatments between
patients and health-care professionals (HCPs).
Particular emphasis is now placed on patient
empowerment, patientsviewsandunderstanding
their needs, priorities, social context and experi-
ences.1,2 To make informed choices about medi-
cines, patients want to know more about their
medicines.3 Consequently, they need reliable and
usable information to use their medicines safely
and eﬀectively, and assist with decision making
based on possible risks and beneﬁts of the medi-
cine.4 Providing patients with medicine informa-
tion can increase knowledge, satisfaction andmay
be an important tool in developing health literacy
through patient education about medicines.5–8
Written medicine information (WMI) is medi-
cine-speciﬁc information for patients, commonly
produced by pharmaceutical manufacturers,
government bodies or third parties from drug
monographs. Many countries have implemented
regulations surrounding access and supply of
WMI. In 1999, the European Union introduced
mandatory, comprehensive package insert WMI
known oﬃcially as the package leaﬂet (PL)9, but
commonly referred to as Patient Information
Leaﬂets (PILs).9 Since the 1970s attempts in the
United States to legislate for WMI have resulted
in government regulations limited to speciﬁc high-
risk medicines. In 1996, an action plan was
developed, but targets set by the Food and Drug
Administration to implement this plan were not
met, and new consultations have begun.10 Aus-
tralian legislation requires manufacturers to
produce WMI known as Consumer Medicine
Information (CMI), for prescription and phar-
macist-only medicines, but does not mandate its
availability as package inserts or its provision to
patients by HCPs.11 The Pharmaceutical Society
of Australia and Society of Hospital Pharmacists
of Australia have produced guidelines to assist
pharmacists to meet legal and professional obli-
gations in ensuring that patients receive the nec-
essary information to make informed
decisions.12,13 Despite CMI being available for
over 16 years, provision rates remain low with
<30% of patients reporting receiving CMI.14
The introduction of pharmacist incentives and
remuneration (althoughminimal and now part of
the dispensing fee), along with stakeholder con-
sultations, and consumer lobbying, has not seen
the desired impact on CMI provision and
utilization.14–16
Although WMI is available for patients inter-
nationally, there are reports of patient dissatis-
faction with quantity, quality and content.2,17,18
WMI is frequently developed without patient
input, often written by manufacturers or persons
whomaybe far removed fromtheuser.Asa result,
WMI content may not meet patients expecta-
tions, needs or priorities – rather serving the
agenda of legislators, medico-legal professionals
or HCPs of increasing medicines adherence.1,19,20
Considering the widespread availability of
WMI, a systematic review found only a small
number of research studies (27 over a period of
30 years) on patient perspectives.19 There is lim-
itedresearchexploringtheunderlyingreasonswhy
WMIisnotmore frequentlyprovidedandutilized,
andwhatmight facilitate increaseduptakeanduse
by patients. Numerous studies have investigated
issuesassociatedwithverbal counsellingor service
provision byHCPs, with a small number focusing
on community pharmacists barriers and facilita-
tors.21–23 However, less attention has been to
directed to patient perceptions.
In understanding the patient perspectives
regarding the barriers and facilitators to the pro-
vision and use of WMI, we can inform future
research, increase awareness and uptake, enhance
eﬀective use, and encourage patient involvement
in their medicine treatment. Thus, the aim of this
study was to explore peoples opinions on their
WMI needs and expectations, and elicit the bar-
riers and facilitators to provision and use.
Methods
Setting and participants
We undertook a qualitative study, using focus
groups, to explore peoples attitudes to and
beliefs about WMI. The participant frame was
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people of 18 years of age and over, who were
taking or had taken at least one prescription
medicine in the last 12 months. People who
could not take part without the help of an
English translator were excluded from the study.
Eligible participants were purposively sampled
with respect to ethnic and socio-economic
backgrounds and were recruited through a
market research company from their large con-
sumer database. Focus group sizes were limited
to six to eight participants. The study received
approval from the Human Research Ethics
Committee of The University of Sydney.
Sixty-two people participated in eight focus
groups. Six groups were held in Sydney and two in
ruralareasofNewSouthWalesover6 weeks in late
2008. The characteristics of the focus group par-
ticipants are shown in Table 1. The groups were
held in a convenient and informal environment,
each lasting between 1 and 1.5 hours and were
audio-recordedwith permission. Participants were
reimbursed a nominal amount for their time.
Focus group conduct
A research team member and experienced health
services researcher (PA) facilitated the focus
groups, with another researcher (KH) observing
and taking notes. Both introduced themselves
and their aﬃliation, but not their speciﬁc pro-
fession (pharmacists), to avoid any bias in
responses. We used a semi-structured interview
guide to allow the discussion to evolve. The
groups began with a general discussion about
participant experiences with WMI, before spe-
ciﬁcally exploring the following key dimensions:
needs and expectations of medicine information;
awareness of the availability of WMI; medicine
information seeking behaviour; and the barriers
and facilitators to WMI provision and use by
patients and HCPs.
Participants were asked to comment on a
selection of WMI leaﬂets from English-speaking
countries (Australia, USA, Canada, New Zea-
land, United Kingdom and Ireland), with the
main discussion concentrating on Australian
CMI. Leaﬂets were selected to be suﬃciently
diﬀerent to provide participants with a sense of
the scope of styles and lengths currently avail-
able worldwide, and put the Australian CMI
into context.
Following each focus group, the two
researchers held a debrieﬁng, discussing emer-
gent themes alongside observation notes. Focus
groups were conducted until no new themes
emerged.24
Data analysis
The audio-recordings were transcribed and
reviewed before thematic content analysis, using
techniques adapted from the grounded theory
method.25 The transcripts were initially open-
coded in conjunction with observation notes.
Open-coding was followed by second-level cod-
ing, to further explore and extract themes to
develop the theoretical framework.26 A system
of constant comparison through cross-refer-
encing of emerging and recognized themes was
used, with data periodically grouped and
regrouped into similar themes through an
inductive process. Two researchers (KH and
PA) independently reviewed the transcripts,
providing separately tabled coding categories
and summaries, which were crosschecked and
reviewed for consistency. Discussion and
Table 1 Characteristics of focus group participants
Participant characteristics n = 62 %
Gender
Male 24 39
Female 38 61
Country of birth
Australia 46 74
Overseas 16 26
Language spoken at home
English 59 95
Other 3 5
Education level
High school 40 65
Diploma or certiﬁcate 7 12
Bachelors 11 18
Post graduate 4 5
Age
21–40 18 29
41–60 20 32
61–80 24 39
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reﬁning of the coding frames reconciled any
discrepancies, with ﬁnalized coding frames
charted then mapped to analyse the range and
interaction of themes.
Findings
The major themes were grouped into ﬁve broad
categories in alignment with the key dimensions
we aimed to explore. There were no observed
diﬀerences in opinions about WMI between
participants from metropolitan and rural areas.
However, there was considerable reliance on
pharmacists for medicine advice and WMI in
rural communities. These communities fre-
quently had issues of accessibility to doctors,
and pharmacists were identiﬁed as a valuable
consultation point. Participants from rural areas
expressed greater satisfaction with, and more
frequent receipt of, WMI from the pharmacist
than their city counterparts.
General experiences with WMI
Signiﬁcantly, most participants did not want
WMI to replace the spoken information they
received from their HCP, stating the face-to-face
interaction with the doctor or pharmacist,
however brief, was valuable because they felt
part of the treatment process.
It is really important when you have that face to
face contact. These [leaﬂets] are great, having
information you can read, but when you have got
a pharmacist that can say ‘‘Righto, this might
happen, that might happen’’, you can say, ‘‘What
will I do?’’ ... I think having a good pharmacist
makes the world of diﬀerence, especially for
someone who may not be well educated, to try and
read this and maybe not know where to start.
(Focus Group 7, Female 1)
Most of these participants thought it impor-
tant to receive written information, believing
that WMI is needed post-consultation as a tool
for reviewing instructions, assisting in informed
decision making and clarifying questions not
raised during prescribing or dispensing. Some
participants wanted WMI, as they felt uncom-
fortable relinquishing control, acknowledging
the possibility that their HCP can make an error
or overlook crucial information. They were
generally active players in their health and felt
responsible for ensuring that decisions about
treatment were not left entirely to others.
However, a number of participants were unin-
terested in receiving WMI, being content with
spoken information, often stating they had a
trusting or positive relationship with their doc-
tor, and saw no need to question the doctors
expertize and training with regard to treatment
decisions.
The majority of participants reported that the
WMI shown could be more patient-centred,
raising the issue of the technical and wordy
nature, and the overall poor usability of most
WMI for the average layperson. Many found
the information to be ambiguous and diﬃcult to
comprehend especially because of the frequent
use of medical jargon and lack of explanations,
thus creating concerns about causing unneces-
sary worry or alarm for recipients, especially
those with English as a second language or
limited literacy.
There was no consensus on the amount of
information participants wished to receive, as
this would depend on individual circumstances
and the perceived seriousness of their condition.
Participants generally indicated a preference for
concise information that summarized a medi-
cines main points, with access via the internet or
their HCP, to comprehensive leaﬂets that
included supplementary disease and lifestyle
information. Some felt that concise medicine
leaﬂets may facilitate HCP provision, allow time
for a brief review with patients and alleviate
concerns of feeling overwhelmed or intimidated
by the visual appearance of the leaﬂet, as many
participants indicated they did. Most stated they
would be more likely to read information that
was shorter and to the point, however, some
agreed that there would be times where more
complete information was desired. Others
wanted nothing left out, expressing concern
about the decision making process associated
with omission of information and felt uneasy
with loss of what could be potentially crucial
information.
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You know I would want everything. I wouldnt want
them to leave out something that might be important
to me. Do you know what I mean? There might be
that one thing …. (FG4, F2)
Most participants felt that a summarized
version of WMI could be delivered as a package
insert to ensure accessibility.
There was a general feeling of suspicion about
the trustworthiness of WMI. The language used
in the leaﬂets produced was perceived as legal-
istic and many questioned the credibility of its
source.
If anything goes wrong see your doctor. It is
encapsulated in all these pages. It is sort of covering
itself. Maybe I have got a suspicious mind, but it just
seems to me that they are sort of shedding any
responsibility from their company onto somebody
else. (FG7, M2)
They felt that an independent source and not
the manufacturer should write the leaﬂets to
make the information valid and unbiased.
Information needs and expectations
Participants discussed the core information
needed to take their medicines safely and
eﬀectively. The common areas identiﬁed
were as follows: side-eﬀects, how to take the
medicine, interactions with drugs and food,
how long to take it and monitoring ⁄ expecta-
tions of the medicines eﬀectiveness, how it
works, storage and disposal. Other points of
information discussed were dosage strength,
missed dose, ingredients, allergies, expiry
date and the long-term eﬀects of taking the
medicine.
The most important element of information
identiﬁed by participants was side-eﬀects, with
many expressing serious concerns about experi-
encing or being aﬀected by them, especially
regarding their quality of life. Side-eﬀect infor-
mation caused a dilemma for participants; there
was the important element of knowing what
could happen, a desire for preparedness, yet
statements by some indicated they intentionally
avoided information due to fear of potential
side-eﬀects and the ensuing worry this caused
them.
We say, why didnt they tell us. We want it both
ways dont we? We want to know then we complain
when they give us the information. Its your choice
isnt it, when you have that choice it comes back to
you. (FG4, F4)
Most participants, however, wanted side-
eﬀect information, and its frequency described
both textually and ⁄or numerically, to aid deci-
sion making and ascertain their personal risk of
experiencing side-eﬀects. Despite the concerns
about side-eﬀects, the majority stated this would
not inﬂuence their adherence.
Participants frequently needed information on
monitoring a medicines eﬀectiveness, noting a
current lack of information both verbally and
written on expected results and timeframes to
achieve these, as an assurance of their medicines
eﬃcacy, and a prompt to seek further consulta-
tion if necessary. Furthermore, many considered
current WMI to be predominantly risk-oriented.
I have yet to read anything that gives you a positive
side eﬀect, you know, you are going to become better
looking if you take it. Every side eﬀect is always
negative. So if you concentrate on the side eﬀects no-
one is ever going to put a tablet in their mouth (FG3,
M2)
They suggested the inclusion of beneﬁt infor-
mation had the potential to oﬀset the negative
side-eﬀect information and provide a balanced
viewpoint, assisting in their assessment of side-
eﬀect risks vs potential beneﬁts of a medicine.
Participants expected to receive information
about alternative medicines or treatment
options, including non-pharmacological and
complementary medicines, to determine the
rightness of the prescribed treatment for them
personally. Some felt that HCPs were generally
unwilling to discuss options other than tradi-
tional medicines and were frustrated that a more
holistic approach was often not adopted. As a
result, they frequently looked for this informa-
tion elsewhere.
Overall, there was a lack of consensus on the
right level of interaction between the partici-
pant, WMI and HCP. During consultations,
some desired a discussion of the medicine leaﬂet,
whilst others wanted it provided on the under-
standing of asking further questions later if
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needed. Some simply wanted to know where to
access a leaﬂet if required.
Awareness and sources of information
Less than half of the participants had received
WMI (as CMI) in the past, and those that did
had requested it whilst seeking further infor-
mation. Few had received a CMI without ask-
ing; the main supplier being the pharmacist, with
a minority receiving it from their doctor. Over-
all, there was limited awareness about CMI
availability, with awareness resulting from
pharmacy advertising, friends or relatives, or
through the prompted (or unprompted) supply
by pharmacists. Interestingly, despite limited
numbers of medicines containing CMI as pack-
age inserts (in Australia), most participants were
aware of them.
The time and situation of delivery of WMI
was seen as crucial. Participants thought the
doctor should logically provide WMI at the time
of prescribing, as many wanted to read it prior
to collecting their medicine to determine its
suitability for them, oﬀering an opportunity to
engage with their doctor in the decision making
process, and to address any concerns or ques-
tions promptly.
If the doctor gave it that would be good because you
leave the doctors surgery with a script, you think oh
yes Im going to get better because theyve given me
this script. Then youre reading it on the way or
waiting in the pharmacy line, then at least you know
well maybe I dont want this…. at least youve got
the information before you ﬁll the script. (FG2, F3)
Doctors were able to prescribe and alter
medicine therapy, knew the patients medical
history and consultations were more personal
than with a pharmacist. Some participants felt
that doctors were generally more abreast of
current information than pharmacists, received
payment for their time and expertize, and had
a duty of care to provide WMI. Most partic-
ipants conceded that time constraints during
consultations were an issue and seemed
resigned to the fact this was unlikely to
change.
In contrast, others thought pharmacists were
a more readily accessible source of medicine
information, typically having more time and
expertize to be able to deal with questions. Many
envisaged the doctor as the diagnostician and
the pharmacist as the medicines expert. The
pharmacist was often seen as the back-up to the
doctor for medicine information and was regu-
larly relied upon by several participants for
advice about their medicine.
Participants frequently used the Internet to
search for WMI, predominantly using Google,
mainly due to a lack of information provided by
HCPs, to double check on spoken information
provided, or to check a medicines suitability.
However, a number of participants were con-
cerned about the quantity of information on the
Internet, the diﬃculties in identifying legitimate
information and their subsequent ability to dis-
seminate the information.
Barriers
Overwhelmingly, the most commonly reported
barrier to receiving WMI was a lack of time,
both HCP consultation and patients time. Par-
ticipants complained that doctor consultation
times were generally too short and they fre-
quently felt conscious of people waiting, often
preventing them from asking for further infor-
mation, including WMI, about their medicines.
Observations speciﬁc to pharmacists were that
business considerations and shopfront sales
often took precedence over what should be
professional obligations concerning patient
medicine information needs.
Interestingly, many participants saw them-
selves as a barrier. Some felt uncomfortable
approaching or discussing medicine informa-
tion with their HCP because of a lack of
conﬁdence or the necessary communication
skills, a lack of positive HCP–patient rela-
tionship or a feeling of powerlessness within
this relationship.
… there is a power imbalance; they are the
authority and you are not… I think patients have
to take responsibility, but not everyone is like that.
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If you are sick, you are a vulnerable person,
and you really go there for help. There is this
power imbalance and I think this is a real problem.
(FG7, M1)
Others thought insuﬃcient demand for WMI
by patients had lead to the lack of routine pro-
vision by HCPs during prescribing or dispens-
ing; predominantly because patients believed it
was available as package inserts in all medicines
or that there was no need for this information
until a problem arose.
Educational limitations, language barriers
(English not primary language) or lack of liter-
acy were other important factors that many felt
inﬂuenced their or other patients desire to seek
WMI. Several participants were not native
English language speakers or had family mem-
bers who relied on them to translate information
for the safe administration and use of medicines,
so they were concerned about the lack of avail-
ability of WMI (as CMI) in Australia in other
languages and the consequent potential for
harm.
The attitude of HCPs to medicine information
provision was seen as not conducive to shared
decision making or patient autonomy by several
participants. The common perception was of
reluctance by HCPs to provide WMI. Partici-
pants thought this may be due to HCP beliefs
that patients might ﬁnd the information scary
and anxiety-causing or feel a sense of ner-
vousness of patients responses to side-eﬀects
and risk information, with HCPs concerned this
could translate to ghost adverse eﬀects, non-
adherence or ceasing the medicine. Some
believed HCPs withheld such information
because it may generate questions they could not
answer, or result in time-consuming or return
consultations.
Accessibility was problematic, with incon-
sistency of provision evident. Although
participants perceived that mandating compul-
sory WMI provision in Australia as package
inserts or via HCPs would address the issue,
some felt that the meaningful interaction
between HCPs and patients could be jeopar-
dized.
Facilitators
Interestingly, despite all the barriers participants
experienced or perceived, many felt ultimately
the responsibility to ask for medicine informa-
tion (written or otherwise), lay with the patient.
They believed it was up to the individual to
facilitate and be proactive about their own
health information needs and that WMI should
be promoted as a tool to empower patients.
The importance of continuity of care through
a regular HCP was seen as a signiﬁcant facili-
tator in fostering a relationship of information
sharing, trust and empathy.
I think everybody should have a relationship with a
pharmacist at least, well equivalent to the doctor.
When you are talking to your doctor there is a sort
of intimate bond between you and the doctor,
because you are relying on him for your health
needs. And then you take the prescription along to
the chemist who knows exactly ... my prescrip-
tions…. I believe in having that same relationship
with my pharmacist as I do with a doctor, and in
return they respond in a similar way (FG7, M2)
Participants also wanted more time with their
HCP during consultation, stating they would be
more likely to ask questions and discuss or seek
clariﬁcation about their medicines. Some indi-
cated their HCP was more likely to oﬀer or
provide, often unprompted, additional medicine
information, including WMI, when unhurried.
They welcomed this worthwhile interaction, with
some commenting that a simple oﬀer of infor-
mation made them feel valued and involved,
feeling as if they had received an extra service,
despite perhaps not initially wanting further
information.
Practically, many participants thought HCPs
could implement software or workﬂow systems
changes to prompt provision. Some suggested
(and had used) self-serve medicine information
kiosks in the past and proposed these be made
more readily available in HCP practices. The use
of internet and multimedia technologies such as
text messaging, emailing and audio ﬁles was
advocated, although there was resistance to this
by several participants because of privacy con-
cerns and ⁄or accessibility by certain sections of
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the community e.g. the elderly. Participants also
recommended advertising WMI availability
within the community, through targeted aware-
ness campaigns, and medicine-focused education
programmes at varying stages of life to encour-
age patient awareness and responsibility for
their medicines.
Discussion
It was clear participants welcomed and valued
written medicine information, and the need for
usable, manageable information was evident.
Despite eﬀorts focusing on readability and
visual presentation, we are still not producing
medicine leaﬂets patients want to use.27,28 Aus-
tralian CMI has the highest compliance on rec-
ommendations for readability and visual
presentation, compared with those from selected
English-speaking countries, yet complaints per-
sist.29 Participant preference was for straight-
forward and easy to understand information
that takes into account the context, logic and
experiences of the patient, in a language they
understand. The varying needs and expectations
of WMI based on personal circumstances sug-
gest that serious consideration be given to the
availability of leaﬂets in diﬀerent formats, as the
current one-size ﬁts all approach may no longer
be adequate in meeting patient needs. The initial
tiering of levels of information through the
shorter style summary leaﬂets, with longer
comprehensive leaﬂets available, could facilitate
improved access and use by HCPs and patients.
Others have proposed this and the future chal-
lenge will be in providing customized tailored
information relevant to patient needs.30
Whilst it was evident that participants wanted
written information about their medicines, they
did not want it to substitute spoken information
from their HCP, echoing other ﬁndings.31–33
Research suggests that around one-third of
patients prefer the doctor to make decisions for
them.34 This may explain the proportion of
participants reporting they were content receiv-
ing no further written information. Our ﬁndings
support existing research concerning patients
accessing and using information in the written
format for use in risk-beneﬁt analysis, informed
decision making and control over their
health.31,35 We conﬁrmed evidence of WMI
being used for reviewing or checking informa-
tion provided by the HCP, for reassurance, to
manage treatment or to ascertain a medicines
suitability.19,36–38 In addition, our participants
speciﬁed wanting written information about
their disease and other treatment options. Pro-
viding and using WMI may not guarantee
decisions about taking medicines will be made
simpler for the patient, but may be the catalyst
necessary to change practice from one of a uni-
lateral decision by the HCP to that of collabo-
ration with the patient, supporting the transition
away from the patient information discourse to
one of patient empowerment.1,2,39
Unsurprisingly, the most important informa-
tion participants wanted to know about was
side-eﬀects.3,18,40 Patients use WMI to prepare
for what they may experience, to identify actions
to take, the likelihood of side-eﬀects, and to
decide whether to take the medicine.3,19 Many
participants felt the leaﬂets were predominantly
risk-oriented and worried that the information
could cause unnecessary concern and anxiety.
Evidence suggests patients want the concomitant
presentation of beneﬁt and harm information
owing to a relationship between risk and beneﬁt
appraisal, providing an explanation of partici-
pants desire for the inclusion of beneﬁt infor-
mation and meriting further research into the
area.33,41
As the majority of participants indicated they
were unaware of the availability of, nor had
received WMI, the option of mandatory provi-
sion as package inserts or through HCPs was a
remedy considered by some participants. A UK
study showed 97% of people noticed and 83%
retained the PIL since implementation of man-
datory package inserts in Europe. Although
71% of ﬁrst-time UK users read some of the
leaﬂet, 60% of repeat-users had subsequently
never or rarely looked at the leaﬂet, indicating
use is still limited, signifying package inserts may
not be the panacea they might seem.42 Further-
more, WMI (as CMI) in Australia is essentially
developed without patient input, and the
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perception that a medico-legal theme predomi-
nates has been noted previously.2,18,19 Unfortu-
nately change could prove diﬃcult, as in practice
strict regulations and legal frameworks govern
the development of patient information by
manufacturers. Diﬀering manufacturer views
and priorities of patients information needs,
and divergent readability and comprehensibility
considerations may contribute to the lack of
patient-centred leaﬂets, highlighting the neces-
sity for substantial emphasis and research on
patient-centred development and testing of
leaﬂets, especially involving the end users.43,44
The desire for more time in HCP consulta-
tions to receive and discuss written information
about their medicines was common among
participants. Pharmacists have also reported
time as a barrier to providing WMI.21,45 Given
the increasing strain on the health-care system, it
is unlikely that consultation time pressures will
reduce. Broadening of paid medicine reviews,
counselling services, and delivery of medicine
information by and beyond that of HCPs, could
be important facilitators to increased provision
and access, and in reducing time burdens upon
HCPs. Considerable progress has been made in
accessibility to health and medicine information
on public websites, supporting a growing trend
of patients searching the Internet for medicine
information, ﬁlling the void left by a lack of
HCP provision.46,47 Recent changes in Australia
provide a centralized patient access point to
WMI (both CMI and Product Information)
through the Therapeutic Goods Administration
website.15 However, access to the Internet has
created challenges for patients in identifying
credible information, and strategies to educate
patients may need to be introduced. With this in
mind and within the context of rapid techno-
logical change and emerging multimedia
options, eﬀective and strategic harnessing of
these technologies could improve access and
communication to patients in their own time, as
well as oﬀering the potential for additional
beneﬁt to those with literacy, language and
visual impairment challenges.48,49
The HCP–patient relationship and continuity
of care are important facets of our analysis that
should not be undervalued. The ability to engage
eﬀectively with WMI is a prerequisite to
informed decision making.48 A lack of HCP
relationship may aﬀect a patients trust and
conﬁdence to discuss their information needs
and is an inﬂuential consideration when con-
templating the problems with WMI provision
and utilization.35 Participants were more likely
to receive information, written or otherwise, ask
for further information, and seek clariﬁcation of
their medicine when they had a positive rela-
tionship with their HCP. Interestingly, partici-
pants indicated satisfaction with even the simple
intervention of the HCPs oﬀering WMI. The
inﬂuence of the HCP–patient relationship
should not be underestimated as HCPs play a
vital role in initiating and encouraging open
discussion about a patients medicines.
Lastly, concerns were raised about the role
literacy played in using WMI. Patients need to
be familiar and conﬁdent with the language and
terminology used, increasing the likelihood of
them reading or using it. The implementation of
educational tools and how-to programmes have
the capacity to act as important facilitators in
assisting patients ability to ﬁnd, understand and
act on information they read, resulting in
improvements in health literacy.49 The
improvement of health literacy may empower
patients, providing them with the knowledge
and conﬁdence to navigate and understand
health information.8
This study contributes to the debate sur-
rounding the patients view of WMI. Many of
our ﬁndings build on prior research on patient
opinions of WMI access, comprehensibility and
use in informed choice and shared decision
making, whilst shedding fresh light on the bar-
riers and facilitators to its provision and use.
The study itself is, however, qualitative and not
generalizable to the entire Australian popula-
tion. We recognize it was conducted with vol-
unteers and is thus limited by the self-selecting
nature. Whilst the study was completed to the-
oretical saturation on a large group of partici-
pants, these ﬁndings do not represent a
consensus or indeed the patients view, rather a
series of views that are context dependent,
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inﬂuenced by various individual health beliefs,
narratives and dynamics within the focus groups
that took place.50 The ﬁndings should thus be
considered as groundwork for further research
into the area.
Conclusion
The factors surrounding the provision and use
of WMI by patients are complex. A one-size ﬁts
all approach may no longer be suitable or
acceptable to patients, and failing to take into
account the needs and preferences of patients
may result in further wasted eﬀort. People want
high-quality information that is legible, com-
prehensible, usable and set within the context of
their needs. WMI should not replace spoken
information, but used to eﬀectively supplement
it. Personal interaction and HCP–patient rela-
tionship is a key component to engaging and
empowering patients in a dialogue about their
medicines. Awareness and accessibility of WMI
should be addressed in conjunction with essen-
tial ongoing medicines education, because sim-
ply providing information, irrespective of
quality, without the how to and why does not
encourage patients to take their medicines con-
ﬁdently, safely and rationally. The issues, espe-
cially of time and HCP attitudes, need to be
tackled as a priority to drive changes to work-
place practices and beliefs. The key to enhanced
WMI use may be to learn from the barriers and
build on the facilitators.
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